Moderna, Inc. (NASDAQ:MRNA) Shares Purchased by Quantinno Capital Management LP

Quantinno Capital Management LP increased its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 658.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 71,298 shares of the company's stock after acquiring an additional 61,892 shares during the quarter. Quantinno Capital Management LP's holdings in Moderna were worth $2,965,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of MRNA. Assenagon Asset Management S.A. raised its stake in Moderna by 13.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 14,978 shares of the company's stock worth $623,000 after acquiring an additional 1,819 shares in the last quarter. Arkadios Wealth Advisors raised its stake in Moderna by 7.3% during the 4th quarter. Arkadios Wealth Advisors now owns 12,265 shares of the company's stock worth $510,000 after acquiring an additional 836 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its stake in Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock worth $44,000 after acquiring an additional 389 shares in the last quarter. Mirabaud & Cie SA raised its stake in Moderna by 3.0% during the 4th quarter. Mirabaud & Cie SA now owns 58,022 shares of the company's stock worth $2,413,000 after acquiring an additional 1,694 shares in the last quarter. Finally, SG Americas Securities LLC raised its stake in Moderna by 108.0% during the 4th quarter. SG Americas Securities LLC now owns 109,761 shares of the company's stock worth $4,564,000 after acquiring an additional 56,982 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have commented on MRNA. Evercore ISI dropped their price objective on shares of Moderna from $50.00 to $32.00 and set an "in-line" rating on the stock in a research note on Friday, May 2nd. Morgan Stanley dropped their price objective on shares of Moderna from $39.00 to $32.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 9th. Citigroup began coverage on shares of Moderna in a research note on Thursday, March 13th. They issued a "neutral" rating and a $40.00 price objective on the stock. Bank of America dropped their price objective on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research note on Tuesday, February 11th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Moderna from $40.00 to $33.00 and set an "underweight" rating on the stock in a research note on Friday, March 21st. Four analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $53.95.

Moderna Trading Up 6.2%

MRNA stock opened at $26.39 on Tuesday. The company has a market cap of $10.21 billion, a P/E ratio of -2.84 and a beta of 1.99. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $170.47. The company's 50-day moving average price is $27.70 and its 200 day moving average price is $35.11.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, topping analysts' consensus estimates of ($2.92) by $0.40. The firm had revenue of $108.00 million for the quarter, compared to the consensus estimate of $130.35 million. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The firm's revenue was down 35.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($3.07) earnings per share. On average, equities research analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.